Table 4.
Risk of hospitalisation after SARS-CoV-2 infection in Denmark, by subvariant
| All | Hospitalised for COVID-19 | Not hospitalised for COVID-19 | OR for difference | Adjusted OR for difference* | |
|---|---|---|---|---|---|
| Main analysis | |||||
| BA.2 | 36 805 | 514 (1·4%) | 36 291 (98·6%) | 1 | 1 |
| BA.5 | 11 314 | 210 (1·9%) | 11 104 (98·1%) | 1·34 (1·14–1·57) | 1·69 (1·22–2·33) |
| Supplementary analysis 1: subgroup analysis in vaccinated individuals† | |||||
| BA.2 | 30 581 | 409 (1·3%) | 30 172 (98·7%) | 1 | 1 |
| BA.5 | 9307 | 178 (1·9%) | 9129 (98·1%) | 1·44 (1·20–1·72) | 1·66 (1·16–2·36) |
| Supplementary analysis 2: extended outcome period‡ | |||||
| BA.2 | 159 943 | 2362 (1·5%) | 157 581 (98·5%) | 1 | 1 |
| BA.5 | 9839 | 203 (2·1%) | 9636 (97·9%) | 1·41 (1·22–1·62) | 1·83 (1·31–2·55) |
| Delta | 526 | 27 (5·1%) | 499 (94·9%) | 3·61 (2·45–5·33) | 2·86 (1·67–4·91) |
Data are n (%), OR (95% CI), or adjusted OR (95% CI). All participants were infected with SARS-CoV-2. The main and supplementary analysis 1 included BA.2 and BA.5 infections that occurred during the outcome period of April 10–June 30, 2022.
Adjusted for age group, time of infection (week number), sex, region of residence, comorbidities, previous infection (except for supplementary analysis 2), and vaccination status (except for supplementary analysis 1).
Received three doses of either mRNA-1273 (lasomeran, Moderna) or BNT162b2 (tozinameran, Pfizer-BioNtech) before March 27, 2022.
Supplementary analysis 2 included BA.2, BA.5, and delta infections that occurred between Jan 1 and June 30, 2022; people with a previous infection before Jan 1, 2022, were excluded.